The new framework aims to accelerate medicines developed in space from research to patient use.
The UK government has announced a new regulatory pathway aimed at bringing medicines made in space closer to patients on Earth, amid growing interest in producing medicines under microgravity conditions.
Officials say the measures aim to give biotech and space companies clearer guidance on how medicines developed in space progress from research in orbit to approved treatments within the UK healthcare system.
The initiative, led by the UK Space Agency with support from multiple regulators, reflects a wider push to position the UK as a leader in on-orbit manufacturing technology, particularly advanced medicines.
Sir David Willetts, head of the UK Space Agency and Department for Regulatory Reform, explained: “Drug manufacturing in orbit is a significant opportunity for the UK, combining the potential for growth in the space sector with the potential for better treatments for patients.
“The UK Space Agency is committed to supporting companies pioneering this research, from microgravity platform providers to biotech and pharmaceutical companies. Setting out a clear implementation pathway with clearly defined regulatory requirements will give investors and entrepreneurs the confidence they need to bring these innovations to market.”
“The UK has world-leading ambition and capability and is open to the business of space-ready medicines.”
Why microgravity is important for drug development
Scientists have long argued that the unique conditions of microgravity can influence how certain medicines are manufactured.
Without the influence of gravity, biological materials such as proteins can form structures that are difficult or impossible to replicate on Earth.
Researchers believe this environment improves the quality and stability of complex biological medicines.
In some cases, more precise crystal formation may be possible in protein-based treatments, which could allow treatments to last longer or be more effective.
These potential improvements are particularly relevant for therapies used to treat cancer, rare diseases, and other conditions that rely on advanced biological medicines.
Government introduces coordinated support package
To support the emerging sector, UK authorities have outlined a series of co-ordination measures aimed at clarifying regulatory expectations for companies pursuing medicines produced in space.
The program involves collaboration between several organizations, including the UK Space Agency, the Medicines and Healthcare products Regulatory Agency (MHRA), the Regulatory Innovation Office (RIO) within the Department of Science, Innovation and Technology (DSIT), and the Civil Aviation Authority (CAA).
The main elements of the package are:
New regulatory guidelines explaining the approval route for medicines produced in microgravity Case studies outlining how companies can navigate the approval process Regulatory sandboxes focused on spacecraft reentry and product return to Earth Increased engagement with supply chain partners involved in in-orbit manufacturing
The aim is to reduce uncertainty for companies developing medicines manufactured in space, while ensuring that safety and quality standards are consistent with existing pharmaceutical regulations.
Alignment with UK Life Sciences Strategy
The initiative is also part of the Government’s £2 billion Life Sciences Sector Plan, which aims to expand treatment options and strengthen the UK’s role in advanced biomedical innovation.
Officials say the strategy recognizes in-orbit manufacturing as a new capability with both economic and scientific implications.
The government has also identified on-orbit maintenance, assembly and manufacturing as priority areas for growth and technological leadership.
Policymakers hope that early clarity on the regulatory process will encourage companies to invest more aggressively in research and demonstration missions focused on space-based production.
Demo mission signals growth in industry activity
Several space missions in conjunction with the UK have already demonstrated technology that could support future manufacturing in orbit.
These include spacecraft designed to test new approaches to satellite maintenance and orbital operations, as well as experimental platforms aimed at returning manufactured materials to Earth.
Meanwhile, the UK Space Agency is funding early-stage research into producing medicines in microgravity.
One such project, known as BioOrbit, is investigating whether protein crystallization performed in orbit could support new forms of cancer treatment that can be performed outside of hospitals.
Dr Paul Bate, CEO of the UK Space Agency, added: “Our investments in innovative projects are consistent with our focused efforts through the Unlock Space Portfolio to connect space companies with pharmaceutical industry and public health partners.
“We want to ensure that promising microgravity research moves toward treatments that improve people’s lives, rather than remaining stagnant in the experimental stage.
“This is about turning the UK’s strengths in space and life sciences into a competitive advantage that benefits patients and growth.”
Preparing for new manufacturing model regulations
Regulators say the existing drug framework can accommodate many forms of advanced manufacturing, but further guidance is needed as new manufacturing environments emerge.
The MHRA has previously developed regulatory approaches for decentralized and modular pharmaceutical production systems.
These models are likely to become increasingly relevant as pharmaceuticals manufactured in space involve decentralized manufacturing processes, specialized supply chains, and transportation between orbit and Earth.
Officials say the updated guidance and sandbox program are aimed at ensuring that regulatory systems evolve with these technologies so that safe and effective medicines developed in space can reach patients if the science proves successful.
Source link
